A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis

• Main Authors: Daniel J. Lovell (Author), Jason A. Dare (Author), Megan Francis-Sedlak (Author), Julie Ball (Author), Brian D. LaMoreaux (Author), Emily Von Scheven (Author), Adam Reinhardt (Author), Rita Jerath (Author), Oral Alpan (Author), Ramesh Gupta (Author), Donald Goldsmith (Author), Andrew Zeft (Author), Henry Naddaf (Author), Beth Gottlieb (Author), Lawrence Jung (Author), Robert J. Holt (Author)
• Format: Book
• Published: BMC, 2018-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Juvenile idiopathic arthritis (JIA) is an inflammatory arthritis of unknown etiology, which lasts for greater than 6 weeks with onset before 16 years of age. JIA is the most common chronic rheumatic disease in children. NSAIDs have been the mainstay of initial management with nap...